对于急性冠状动脉综合征中左侧与非左侧冠状动脉进行皮肤冠状动脉干预的结果:一项比较研究
S M Mamun Iqbal1, A M Shafique2, Neuton Mondal1
1Department of Cardiology, MH Samorita Hospital and Medical College, Dhaka, BGD.
Cureus
|October 3, 2025
概括
针对影响左主冠状动脉 (LMCA) 的急性冠状动脉综合征 (ACS) 进行皮肤穿冠状动脉干预 (PCI) 的患者,与非LMCA参与者相比,面临更高的心血管不良事件风险,包括心肌梗塞和重复血管化.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 心血管医学 心血管医学
背景情况:
- 涉及左主冠状动脉 (LMCA) 的急性冠状动脉综合征 (ACS) 与显著的发病率和死亡率有关.
- 穿皮冠状动脉干预 (PCI) 是ACS的关键治疗方法.
- 对于LMCA-ACS的PCI结果需要进一步调查.
研究的目的:
- 为了比较影响LMCA的ACS患者与非LMCA参与患者的PCI的长期结果.
- 评估主要心血管不良事件 (MACE) 的发生率和PCI后的二次终点.
- 确定与LMCA参与ACS.相关的风险因素.
主要方法:
- 一项干预性研究涉及101名接受PCI的ACS患者.
- 患者被分为两组:LMCA参与 (n=51) 和非LMCA参与 (n=50).
- 3,6和12个月的后续评估监测了MACE,持续的症状,重复的血管化和支架血栓形成.
主要成果:
- 与非LMCA组 (2%) 相比,LMCA组的MACE率更高 (6%) (p=0.013).
- 心肌梗塞 (MI) 发生在LMCA组的4%,而非LMCA组没有事件.
- 在LMCA组中观察到更高的持续症状和重复复血管化率.
结论:
- 涉及LMCA的ACS与PCI后显著更高的不良心血管结果率有关.
- 对于LMCA-ACS的PCI需要仔细考虑,因为它增加了心脏病发作和重复血管化的风险.
- 需要进一步的研究来优化LMCA-ACS患者的PCI策略.
相关概念视频
01:30Acute Coronary Syndrome I: Introduction
804
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
804
01:24Cardiac Catheterization III: Left Heart Catheterization
577
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
577
01:28Acute Coronary Syndrome IV: Interprofessional Care
219
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
219
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
354
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
354
01:30Acute Coronary Syndrome III: Diagnostic Studies
213
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
213
01:27Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215